Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 2Phase 1/2 1

Status

Recruiting 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 4UNKNOWN 1INDUSTRY 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Gastrointestinal 6Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Carcinoma, Hepatocellular 18Neoplasms 13Neoplasm Metastasis 13Melanoma 13Esophageal Neoplasms 12Nasopharyngeal Carcinoma 10Head and Neck Neoplasms 9Esophageal Squamous Cell Carcinoma 9Colorectal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Recurrence 7Pancreatic Neoplasms 7Rectal Neoplasms 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3

Interventions

Fluorouracil 267Oxaliplatin 266Capecitabine 224Leucovorin 209Irinotecan 151Radiotherapy 131Bevacizumab 112Cetuximab 81Folfox protocol 48Surgical Procedures, Operative 44Radiation 41Drug Therapy 41Neoadjuvant Therapy 40Chemoradiotherapy 33Chemotherapy, Adjuvant 32Panitumumab 27XELOX 25Magnetic Resonance Spectroscopy 22Radiotherapy, Intensity-Modulated 21Floxuridine 17Biopsy 16Nivolumab 15Gemcitabine 15Early Intervention, Educational 15pembrolizumab 14Laparoscopy 14IFL protocol 14Celecoxib 14trifluridine tipiracil drug combination 13Gene Expression Profiling 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Rectal Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer(CONTROL-01)

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06710847 2026-02-02

SYLVER

GlaxoSmithKline

Phase 1/2 Active not recruiting
14 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06958432 2025-08-07

Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2/3 Recruiting
430 enrolled
Gastrointestinal

Rectal Neoplasms

NCT05450029 2023-09-26

SILAR

Sun Yat-sen University

Phase 2 Recruiting
51 enrolled
Gastrointestinal

Rectal Neoplasms

NCT05507112 2022-09-21

TIMENT-R

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
100 enrolled
Gastrointestinal

Rectal Neoplasms

NCT05484024 2022-08-02

Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer

ChineseAMS

Phase 2/3 Not yet recruiting
588 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡